DekaBank Deutsche Girozentrale Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

DekaBank Deutsche Girozentrale decreased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 113,586 shares of the company’s stock after selling 2,637 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.11% of Neurocrine Biosciences worth $15,212,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of NBIX. Mather Group LLC. purchased a new position in Neurocrine Biosciences in the 1st quarter worth about $26,000. RFP Financial Group LLC raised its position in Neurocrine Biosciences by 346.5% in the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after buying an additional 149 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in Neurocrine Biosciences in the 2nd quarter worth about $28,000. Innealta Capital LLC purchased a new position in Neurocrine Biosciences in the 2nd quarter worth about $30,000. Finally, New Covenant Trust Company N.A. purchased a new position in Neurocrine Biosciences in the 1st quarter worth about $32,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

NBIX has been the subject of a number of recent analyst reports. Guggenheim boosted their target price on Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. BMO Capital Markets reduced their price target on shares of Neurocrine Biosciences from $142.00 to $128.00 and set a “market perform” rating for the company in a research report on Thursday, August 29th. Barclays reduced their price target on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Wedbush reaffirmed an “outperform” rating and set a $152.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, May 29th. Finally, JPMorgan Chase & Co. upped their price target on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $162.20.

Insider Transactions at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 273 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total transaction of $40,322.10. Following the sale, the insider now directly owns 6,607 shares of the company’s stock, valued at approximately $975,853.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Ingrid Delaet sold 273 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total transaction of $40,322.10. Following the sale, the insider now directly owns 6,607 shares of the company’s stock, valued at approximately $975,853.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gary A. Lyons sold 930 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $150.03, for a total value of $139,527.90. Following the sale, the director now directly owns 119,047 shares in the company, valued at $17,860,621.41. The disclosure for this sale can be found here. Insiders have sold 71,798 shares of company stock valued at $10,676,096 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Price Performance

NBIX stock opened at $122.25 on Monday. Neurocrine Biosciences, Inc. has a 1-year low of $103.63 and a 1-year high of $157.98. The company has a market capitalization of $12.34 billion, a price-to-earnings ratio of 33.68 and a beta of 0.37. The business has a 50 day simple moving average of $140.95 and a two-hundred day simple moving average of $138.62.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The business had revenue of $590.20 million during the quarter, compared to the consensus estimate of $545.98 million. During the same quarter in the previous year, the company earned $0.95 earnings per share. The company’s revenue for the quarter was up 30.4% compared to the same quarter last year. Sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.